Wall Street Zen Upgrades Nutex Health (NASDAQ:NUTX) to Strong-Buy

Nutex Health (NASDAQ:NUTX) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Friday.

Several other brokerages have also recently weighed in on NUTX. Weiss Ratings upgraded Nutex Health from a “sell (d)” rating to a “hold (c)” rating in a report on Tuesday. Maxim Group set a $205.00 price objective on Nutex Health and gave the company a “buy” rating in a research report on Tuesday, August 26th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $252.50.

Nutex Health Trading Up 4.0%

NUTX stock opened at $117.28 on Friday. The company has a market capitalization of $829.40 million, a PE ratio of 9.86 and a beta of -0.23. The company has a debt-to-equity ratio of 1.02, a quick ratio of 2.26 and a current ratio of 2.27. Nutex Health has a one year low of $28.12 and a one year high of $184.27. The company’s 50 day moving average price is $112.98 and its two-hundred day moving average price is $113.45.

Nutex Health (NASDAQ:NUTX) last released its earnings results on Tuesday, November 18th. The company reported $7.76 EPS for the quarter, beating the consensus estimate of ($5.43) by $13.19. The company had revenue of $243.99 million for the quarter, compared to analyst estimates of $221.93 million. Nutex Health had a net margin of 10.76% and a return on equity of 42.08%.

Insider Buying and Selling at Nutex Health

In related news, CFO Jon Christian Bates bought 750 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were purchased at an average cost of $136.71 per share, with a total value of $102,532.50. Following the completion of the purchase, the chief financial officer owned 5,638 shares in the company, valued at approximately $770,770.98. The trade was a 15.34% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 36.92% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of NUTX. PharVision Advisers LLC purchased a new position in shares of Nutex Health during the third quarter valued at approximately $420,000. Quarry LP bought a new stake in Nutex Health in the 3rd quarter worth approximately $610,000. Millennium Management LLC grew its position in Nutex Health by 191.1% in the 3rd quarter. Millennium Management LLC now owns 93,396 shares of the company’s stock worth $9,650,000 after purchasing an additional 61,308 shares during the period. Bank of America Corp DE raised its stake in Nutex Health by 197.3% during the 3rd quarter. Bank of America Corp DE now owns 11,045 shares of the company’s stock valued at $1,141,000 after buying an additional 7,330 shares during the last quarter. Finally, Topline Capital Management LLC lifted its holdings in shares of Nutex Health by 80.0% during the 3rd quarter. Topline Capital Management LLC now owns 556,567 shares of the company’s stock valued at $57,505,000 after buying an additional 247,436 shares during the period. Hedge funds and other institutional investors own 5.32% of the company’s stock.

About Nutex Health

Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.